Exhibit 99.1

	November 14, 2008 — Frequently Asked Questions and Answers — (FAQs)
	From time to time, Investor Relations will provide FAQs on various topics of interest. The following is a recent FAQ.
Q	What are the IMS prescription volumes for VYTORIN and ZETIA?
A	U.S. Total Prescription Volume (000’s)

	Jan.		Feb.		March		April		May		June
	2008		2008		2008		2008		2008		2008
Cholesterol Management Market		20,519		19,042		19,788		19,645		19,910		19,403
Total Merck/Schering-Plough Franchise		3,226		2,790		2,820		2,507		2,479		2,351
VYTORIN		1,851		1,607		1,619		1,428		1,412		1,330
ZETIA		1,375		1,183		1,201		1,079		1,067		1,022

	July		Aug.		Sept.		Oct.
	2008		2008		2008		2008
Cholesterol Management Market		20,292		19,666		19,923		20,640
Total Merck/Schering-Plough Franchise		2,376		2,233		2,171		2,186
VYTORIN		1,339		1,249		1,202		1,207
ZETIA		1,038		984		969		978

Source: IMS’ National Prescription Audit Plus (NPA+) as of November 12, 2008 which includes routine refinements by IMS to previously published data.

DISCLOSURE NOTICE: The information in the frequently asked questions included in this FAQ, and in other written and oral statements about Schering-Plough and its business made by Schering-Plough or its officers from time to time, includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to prescription trends for VYTORIN and ZETIA.

Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough’s forward-looking statements, including market forces (such as customer buying patterns); economic factors; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the timing and outcomes of the regulatory process; the timing and outcomes of clinical trials; and prescriber, patient and media reaction to data obtained from post-marketing clinical trials, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough’s Securities and Exchange Commission filings, including Part II, Item 1A. “Risk Factors” in the third quarter 2008 10-Q, filed October 29, 2008.